More than 1,000 clinical trials were stopped by the pandemic — including dozens in PhIII
We’ve been hearing plenty of anecdotal evidence of the damage done by the Covid-19 outbreak globally to drug R&D. But a researcher now based in Berlin trawled the data available online and came up with a startling conclusion: at least 1,099 trials have been halted by the coronavirus.
The vast majority of these studies — 97%, or 1,070 — were suspended, a temporary halt that could allow them to resume once the new virus has been tamed and sites reopened. But it may not be that simple.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 83,000+ biopharma pros reading Endpoints daily — and it's free.